Home > Insider Trading > Filing (0000899243-20-003025)

Filing Details

Accession Number:: 0000899243-20-003025
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-02-04 20:44:12
Reporting Period:: 2020-02-01

Accepted Time:: 2020-02-04 20:44:12
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1629137	Global Blood Therapeutics Inc.	GBT	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1238408	Borga Tricia Suvari	C/O Global Blood Therapeutics, Inc. 171 Oyster Point Blvd., Suite 300 South San Francisco CA 94080	Chief Legal Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-01-31	401	$36.68	8,749	No	5	A	Direct
Common Stock	Acquisiton	2020-02-01	6,375	$0.00	15,124	No	4	M	Direct
Common Stock	Disposition	2020-02-01	2,295	$65.26	12,829	No	4	F	Direct
Common Stock	Disposition	2020-02-03	1,308	$62.81	11,521	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	5	A	Direct
No	4	M	Direct
No	4	F	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2020-02-01	3,250	$0.00	3,250	$0.00
Common Stock	Restricted Stock Units	Disposition	2020-02-01	3,125	$0.00	3,125	$0.00
Common Stock	Restricted Stock Units	Acquisiton	2020-02-03	24,160	$0.00	24,160	$0.00
Common Stock	Stock Option (Right to Buy)	Acquisiton	2020-02-03	38,500	$0.00	38,500	$65.82

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
13,000		No	4	M	Direct
18,750		No	4	M	Direct
24,160		No	4	A	Direct
38,500	2030-02-02	No	4	A	Direct

Footnotes

Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 6,375 shares of Common Stock underlying the Reporting Person's RSUs.
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
The shares of Common Stock underlying the option vest in 16 equal quarterly installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.